• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

    3/27/24 1:12:56 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMRX alert in real time by email
    SC 13G/A 1 sc13ga032724.htm SC 13G/A Merrin Investors LLC

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

     

    Immuneering Corp.

     

    (Name of Issuer)

     

    Class A Common Stock

     

    (Title of Class of Securities)

     

    45254E107

    (CUSIP Number)

     

    March 14, 2024

    (Date of Event which Requires Filing

    of this amended Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      o Rule 13d-1(b)
      x Rule 13d-1(c)
      o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

      

     

     

    Page 1 of 5
     
     

     

     

    CUSIP No. 45254E107          

     

     

    13G

     

     

    Page 2 of 5 Pages

     

     

     

    1

     NAME OF REPORTING PERSON

     

     Merrin Investors LLC

     

     

    2

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

    (b) ☐

     

    3

     SEC USE ONLY

     

     

    4

     CITIZENSHIP OR PLACE OF ORGANIZATION

      Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED

    BY
    EACH
    REPORTING
    PERSON

    WITH:

     

     

    5

     SOLE VOTING POWER

     2,770,386

     

    6

     SHARED VOTING POWER

     0

     

     

    7

     

     SOLE DISPOSITIVE POWER

     2,770,386

     

     

    8

     

     SHARED DISPOSITIVE POWER

     0

     

     

    9

     

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     2,770,386

     

     

    10

     

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     ☐

     

     

    11

     

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     9.46%

     

     

    12

     

     TYPE OF REPORTING PERSON

     OO

     

     

     

    Page 2 of 5

     
     

     

    Item 1(a) Name of Issuer:
       
      Immuneering Corp.
       
    Item 1(b) Address of Issuer's Principal Executive Offices:
       
      245 Main Street, Second Floor, Cambridge, Massachusetts 02142
       
    Item 2(a) Name of Person Filing:
       
      This statement is filed by Merrin Investors LLC with respect to shares of Class A Common Stock the Issuer. Seth Merrin is the managing member of Merrin Investors LLC and as such has voting and dispositive power over the securities held of record by Merrin Investors LLC.
       

    Item 2(b)

     

    Address or Principal Business Office:

     

      The address of the principal business office of Merrin Investors LLC is 2547 Maple Avenue, Cortlandt Manor, NY 10567.
       
    Item 2(c) Place of Organization:
       
      Delaware
       
    Item 2(d) Title of Class of Securities:
       
      Class A Common Stock
       
    Item 2(e) CUSIP Number:
       
      45254E107
       
    Item 3 Not Applicable
       
    Item 4 Ownership:
       
      Reference is made to Items 5-11 in this Schedule13G.
       

     

     

     

    Page 3 of 5
     
     

    Item 5 Ownership of Five Percent or Less of a Class:
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.  ☐
       
    Item 6 Ownership of More than Five Percent on Behalf of Another Person:
       
      Not Applicable
       
    Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
       
      Not Applicable
       
    Item 8 Identification and Classification of Members of the Group:
       
      Not Applicable
       
    Item 9 Notice of Dissolution of Group:
       
      Not Applicable
       
    Item 10 Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

      

     

     

     

     

     

     

     

     

    Page 4 of 5

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: March 27, 2024

     

    MERRIN INVESTORS LLC

     

    By: /s/ Seth Merrin                                                                                                  

    Name: Seth Merrin

    Title Managing Member

     

     

     

     

     

     

     

     

     

     

     

     

     

     

      

     

     

    Page 5 of 5

     

    Get the next $IMRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMRX

    DatePrice TargetRatingAnalyst
    7/8/2026$17.00Overweight
    Cantor Fitzgerald
    10/31/2025$15.00Outperform
    Leerink Partners
    12/13/2024Equal-Weight → Underweight
    Morgan Stanley
    3/15/2024$20.00 → $15.00Buy
    Needham
    3/15/2024Outperform → Market Perform
    TD Cowen
    3/15/2024$16.00 → $3.00Buy → Hold
    Jefferies
    12/1/2023$20.00Buy
    Needham
    6/26/2023$25.00Outperform
    Oppenheimer
    More analyst ratings

    $IMRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Immuneering with a new price target

    Cantor Fitzgerald initiated coverage of Immuneering with a rating of Overweight and set a new price target of $17.00

    7/8/26 9:28:11 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Immuneering with a new price target

    Leerink Partners initiated coverage of Immuneering with a rating of Outperform and set a new price target of $15.00

    10/31/25 8:20:02 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation downgraded by Morgan Stanley

    Morgan Stanley downgraded Immuneering Corporation from Equal-Weight to Underweight

    12/13/24 8:04:38 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    SEC Filings

    View All

    Immuneering Corporation filed SEC Form 8-K: Leadership Update

    8-K - Immuneering Corp (0001790340) (Filer)

    6/15/26 4:12:31 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Immuneering Corp (0001790340) (Filer)

    6/11/26 5:16:14 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation filed SEC Form 8-K: Other Events

    8-K - Immuneering Corp (0001790340) (Filer)

    6/1/26 4:51:53 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition

    - Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constrained other MEK inhibitors - - In head-to-head in vivo studies, atebimetinib produced deeper, more durable tumor growth inhibition than the FDA-approved MEK inhibitor binimetinib - - Atebimetinib was associated with favorable tolerability in preclinical models, consistent with Deep Cyclic Inhibitor technology’s design to decouple antitumor activity from the toxicity of continuous MAPK suppression - - In a preclinical cancer cachexia model, atebimetinib-treated animals sustained body weight near b

    7/21/26 4:05:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation Announces Grants of Inducement Awards

    NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously announced on June 15, 2026, that Andrew Gengos was named Chief Financial Officer of the Company, effective as of July 16, 2026 (the "Start Date"). In connection with the commencement of Mr. Gengos’s employment, on July 16, 2026, Mr. Gengos was granted an option to purchase 650,000 shares of the Company’s Class A common stock ("Common Stock") with a per share exercise price of $4.78, the closing trading price of the Common Stock on the Nasdaq Global Market on July 16, 2026 (the "Closing Price").

    7/17/26 4:05:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kalaris Appoints Laurie Keating to Board of Directors

    BERKELEY HEIGHTS, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. In conjunction with the announcement of Ms. Keating’s appointment, Morana Jovan-Embiricos is stepping down from the Board of Directors. "We’re delighted to welcome Laurie to the Kalaris Board of Directors. She has extensive strategic, operational, and legal expertise spanning multiple therapeutic areas and development stages. Laurie will be

    7/6/26 4:05:00 PM ET
    $KLRS
    $PEPG
    $IMRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $IMRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT AND CEO Zeskind Benjamin J. bought $10,948 worth of shares (2,400 units at $4.56), increasing direct ownership by 0.10% to 2,315,252 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    6/24/26 4:11:29 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought $25,045 worth of shares (6,035 units at $4.15), increasing direct ownership by 2% to 382,531 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    6/16/26 4:15:14 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business Officer Brakewood Harold Eugene bought $24,990 worth of shares (5,250 units at $4.76), increasing direct ownership by 91% to 11,050 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/21/26 9:09:57 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Gengos Andrew

    4 - Immuneering Corp (0001790340) (Issuer)

    7/17/26 4:29:06 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Gengos Andrew claimed ownership of 225,000 shares (SEC Form 3)

    3 - Immuneering Corp (0001790340) (Issuer)

    7/16/26 4:10:38 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Zeskind Benjamin J. bought $10,948 worth of shares (2,400 units at $4.56), increasing direct ownership by 0.10% to 2,315,252 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    6/24/26 4:11:29 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Leadership Updates

    Live Leadership Updates

    View All

    Kalaris Appoints Laurie Keating to Board of Directors

    BERKELEY HEIGHTS, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. In conjunction with the announcement of Ms. Keating’s appointment, Morana Jovan-Embiricos is stepping down from the Board of Directors. "We’re delighted to welcome Laurie to the Kalaris Board of Directors. She has extensive strategic, operational, and legal expertise spanning multiple therapeutic areas and development stages. Laurie will be

    7/6/26 4:05:00 PM ET
    $KLRS
    $PEPG
    $IMRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

    NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tavneos®, a first-in-class oral therapy for ANCA-associated vasculitis. Under his leadership, ChemoCentryx was acquired by Amgen in 2022 for nearly $4 billion. His career

    9/16/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

    - Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone - - First Patient Dosed in Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations; Initial PK, PD and safety data expected in 2024 - CAMBRIDGE

    5/7/24 4:05:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Financials

    Live finance-specific insights

    View All

    Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

    - 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study - - Only two categories of Grade 3+ treatment-related adverse events occurring in ≥10% of patients, both chemotherapy related - - 84% of participants maintained or gained weight at three months - - Global Phase 3 MAPKeeper 301 trial (NCT07562152) in first-line metastatic pancreatic cancer actively recruiting, with first patient dosing expected in mid-2026 - - Company to hold investor conference call today, at 8:00 a.m. EDT - NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical

    6/1/26 7:30:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

    - Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 - - Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related - - Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST - NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported a 17.3-month median overall survival (OS) in first-line metastatic pancreatic cancer patients treated in its Phas

    5/21/26 5:00:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

    - Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall survival remains unreached as of data cutoff, suggesting encouraging durability of clinical benefit - - Anticipate dosing first patient in pivotal Phase 3 clinical trial, MAPKeeper 301, in mid-2026 - - Company to host conference call at 4:30 p.m. ET today - NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping

    1/7/26 4:00:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    11/14/24 4:15:35 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    11/14/24 3:03:47 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    4/15/24 6:10:57 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care